Y
Yong Lin
Researcher at Eli Lilly and Company
Publications - 19
Citations - 1232
Yong Lin is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Cancer & Fulvestrant. The author has an hindex of 8, co-authored 19 publications receiving 847 citations.
Papers
More filters
Journal ArticleDOI
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
George W. Sledge,Masakazu Toi,Patrick Neven,Joohyuk Sohn,Kenichi Inoue,Xavier Pivot,Olga Burdaeva,Meena Okera,Norikazu Masuda,Peter A. Kaufman,Han Koh,EM Grischke,Martin Frenzel,Yong Lin,Susana Barriga,Ian C. Smith,Nawel Bourayou,Antonio Llombart-Cussac +17 more
TL;DR: Abemaciclib at 150 mg twice daily plus fulvestrant was effective, significantly improving PFS and ORR and demonstrating a tolerable safety profile in women with hormone receptor-positive and human epidermal growth factor receptor 2-negative ABC who progressed while receiving ET.
Journal ArticleDOI
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
J. Randolph Hecht,Sara Lonardi,Johanna C. Bendell,Hao-Wen Sim,Teresa Macarulla,Charles D. Lopez,Eric Van Cutsem,Andres J. Muñoz Martin,Joon Oh Park,Richard Greil,Hong Wang,Rebecca R. Hozak,Ivelina Gueorguieva,Yong Lin,Sujata Rao,Baek Yeol Ryoo +15 more
TL;DR: PEG added to FOLFOX did not improve efficacy in advanced gemcitabine-refractory PDAC, and pharmacodynamic results were consistent with immunostimulatory signals of the IL-10R pathway.
Journal ArticleDOI
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy
Angelo Di Leo,Joyce O'Shaughnessy,George W. Sledge,Miguel Martin,Yong Lin,Martin Frenzel,Molly C. Hardebeck,Ian C. Smith,Antonio Llombart-Cussac,Matthew P. Goetz,Stephen R. D. Johnston +10 more
TL;DR: Analysis of patient and disease characteristics and prognostic factors found that patients with certain indicators of poor prognosis—including liver metastases, progesterone receptor negativity, high-grade tumors, or short treatment-free intervals following the completion of adjuvant endocrine therapy—benefited most from abemaciclib, as measured by progression-free survival.
Journal ArticleDOI
Randomized Phase III Study of FOLFOX Alone and with Pegilodecakin as Second-line Therapy in Patients with Metastatic Pancreatic Cancer (SEQUOIA).
J. Randolph Hecht,Sara Lonardi,Johanna C. Bendell,Hao-Wen Sim,Teresa Macarulla,Charles D. Lopez,Eric Van Cutsem,Andres J. Muñoz Martín,Joon Oh Park,Richard Greil,Yong Lin,Sujata Rao,Baek-Yeol Ryoo +12 more
TL;DR: This data indicates that six patients with advanced metastatic pancreatic ductal adenocarcinoma who have progressed after 1st line gemcitabine-based chemotherapy (Gem)...
Journal ArticleDOI
MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy
George W. Sledge,Masakazu Toi,Patrick Neven,Joohyuk Sohn,Kenichi Inoue,Xavier Pivot,Olga Burdaeva,Meena Okera,Norikazu Masuda,Peter A. Kaufman,Han A. Koh,Eva-Maria Grischke,Martin Frenzel,Yong Lin,Susana Barriga,Ian C. Smith,Nawel Bourayou,Antonio Llombart-Cussac +17 more
TL;DR: Abemaciclib, an oral, selective inhibitor of CDK4 & 6, dosed on a continuous schedule, demonstrated clinical activity as monotherapy in patients with treatment refractory horm...